Looking for an OpenEvidence Alternative in the UK?

OpenEvidence is no longer available to UK doctors. The platform withdrew from the UK and EU on 28 April 2026, citing uncertainty around AI regulation. It went quietly — no replacement announced, no UK handoff.

If you used it, you'll have noticed the gap.

Update — 1 June 2026 (five weeks on): OpenEvidence is still unavailable to UK clinicians, and no re-entry signal has been published. The UK regulatory framework that triggered the withdrawal remains mid-flight — the MHRA Medical Devices (Amendment) Regulations consultation closes 19 June 2026; the International Reliance Framework is expected in Autumn. The clinical-AI press has caught up with the issue: a position piece in The Lancet Regional Health – Europe — The Need for Regulatory Certainty on Medical AI: Lessons From the OpenEvidence Geoblocking in the EU and UK Over the EU AI Act (De Angelis L, Sacchi F, Pappalardo C, et al., 2026) — examines the geoblocking of clinical AI tools and the EU AI Act. What has changed since April is the alternatives — see the table below.

What happened

OpenEvidence was the leading AI clinical Q&A tool in the US — used by over 40% of American physicians. In January 2026 it raised $250m at a $12 billion valuation. By the end of April, it was gone from the UK.

The stated reason was regulatory uncertainty around AI in healthcare. The EU AI Act and the UK's AI regulatory landscape are unsettled enough that several US AI health tools have paused UK expansion or withdrawn entirely. ChatGPT for Clinicians launched the same week and explicitly excluded UK and EEA users. Heidi Evidence — the clinical decision support tool partnered with NICE, BMJ Group, MIMS and HealthPathways — joined the pattern in 2026 by restricting its UK and EU evidence querying to out-of-session use only.

UK doctors have now seen three credible clinical AI tools pull back from point-of-care use in six weeks — two withdrawn, one restricted to out-of-session use.

What OpenEvidence actually did

OpenEvidence answered clinical questions with referenced, peer-reviewed sources. You typed a question — "what's the evidence on palliative sedation in refractory distress?" — and it returned a synthesised, referenced answer.

It was a point-of-care Q&A tool. Useful when you wanted a referenced answer faster than a PubMed search.

It was not a tool for keeping up with the literature. It didn't surface what was new. It answered what you already knew to ask about.

That distinction matters, because these are two different problems.

The alternatives have matured (June 2026)

When OpenEvidence withdrew in April, the field of UK-usable replacements was thin. Five weeks on, it is fuller — but the picture is still uneven, because most of these are query tools and several are not actually open to UK NHS clinicians yet.

The query tools above — iatroX, Heidi Evidence, Praxis, Vera, ClinicalKey AI and UpToDate — help you ask a question. None of them keep you current. That is a different job, and it is the one MCB does. Think of the digest as the reading layer none of these replace: it tells you what changed this week, so you know what to ask the query tool about in the first place.

One loop worth closing: Heidi Evidence now publishes its own "OpenEvidence alternative" comparison — while its own answer feature is restricted to out-of-session use for UK and EU clinicians. So a UK doctor who follows that recommendation lands on a tool they cannot use in the consultation itself. If that is you, the usable options above (and a weekly digest for the reading) are the practical answer.

For clinical Q&A: what's still available in the UK

iatroX is UK-based, holds MHRA registration and UKCA marking, and is positioning as the UK alternative for AI clinical Q&A. It's the closest direct replacement for OpenEvidence's core use case within the UK regulatory environment.

Two established names belong here too, with an important difference between them. ClinicalKey AI (Elsevier) is the genuinely UK-available one — individual UK clinicians can subscribe (there's a free trial), and it answers from Elsevier's peer-reviewed library. UpToDate is the other: the standard reference is everywhere in the NHS via institutional access, but its generative AI Q&A layer — Pro Plus AI for individuals (US and Canada only) and Expert AI for enterprise (limited availability outside the US) — isn't something a UK individual can reach today (see MCB vs UpToDate). So for an AI answer you can actually use in the UK, ClinicalKey AI counts; UpToDate's AI layer mostly doesn't, yet. Either way, both answer what you ask — not what's new.

For keeping up with the literature: that's a different problem

OpenEvidence couldn't tell you about a practice-changing trial published last month unless you already knew to ask about it. Most clinicians don't.

The problem of staying current — knowing what's new, what matters, and what might change how you practice — doesn't get solved by Q&A tools. It gets solved by reading. And most clinicians don't have time to read.

That is the problem we built The Monday Clinical Brief to solve.

What The Monday Clinical Brief offers

Every Monday morning, we send you every new peer-reviewed paper published that week in the five highest-impact journals in your specialty. Plain-language summaries. Links to the originals. Nothing else.

We cover 31 specialties. We do the curation. You stay current.

£20 a year. No app. No algorithm. No login required.

Subscribe to The Monday Clinical Brief and never miss a practice-changing paper again.

The bottom line

OpenEvidence was good at answering questions you already had. For that job in the UK, iatroX is worth a look.

But staying current with the literature — knowing what questions to ask in the first place — is a different problem. If that's the one you're trying to solve, that's what we're here for.

Related reading

• Two AI tools UK doctors lost, one restricted — and what works in their place — the wider pattern, with a practical two-tool setup for UK clinicians.
• ChatGPT for Clinicians launched — and UK doctors are excluded
• Heidi Evidence is excellent — and in the UK it won't answer mid-consultation